Nothing Special   »   [go: up one dir, main page]

NO20074037L - Farmasoytiske formuleringer med vedvarende frigivelse - Google Patents

Farmasoytiske formuleringer med vedvarende frigivelse

Info

Publication number
NO20074037L
NO20074037L NO20074037A NO20074037A NO20074037L NO 20074037 L NO20074037 L NO 20074037L NO 20074037 A NO20074037 A NO 20074037A NO 20074037 A NO20074037 A NO 20074037A NO 20074037 L NO20074037 L NO 20074037L
Authority
NO
Norway
Prior art keywords
sustained
pharmaceutical formulations
release pharmaceutical
release
formulations
Prior art date
Application number
NO20074037A
Other languages
English (en)
Inventor
Srikonda Sastry
Janaki Nyshadham
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20074037L publication Critical patent/NO20074037L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Beskrevet er nye ranolazin-farmasøytiske formuleringer med vedvarende frigivelse.
NO20074037A 2005-01-06 2007-08-03 Farmasoytiske formuleringer med vedvarende frigivelse NO20074037L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64216805P 2005-01-06 2005-01-06
PCT/US2006/000503 WO2006074398A2 (en) 2005-01-06 2006-01-05 Sustained release pharmaceutical formulations comprising ranolazine

Publications (1)

Publication Number Publication Date
NO20074037L true NO20074037L (no) 2007-08-03

Family

ID=36648222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074037A NO20074037L (no) 2005-01-06 2007-08-03 Farmasoytiske formuleringer med vedvarende frigivelse

Country Status (16)

Country Link
US (1) US20060177502A1 (no)
EP (1) EP1841411A2 (no)
JP (1) JP2008526879A (no)
KR (1) KR20070093988A (no)
CN (1) CN101098682A (no)
AU (1) AU2006203890A1 (no)
BR (1) BRPI0606403A2 (no)
CA (1) CA2593593A1 (no)
GE (1) GEP20094784B (no)
IL (1) IL184460A0 (no)
MX (1) MX2007008162A (no)
NO (1) NO20074037L (no)
RU (1) RU2384332C2 (no)
UA (1) UA90875C2 (no)
WO (1) WO2006074398A2 (no)
ZA (1) ZA200705530B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1505977B1 (en) 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
WO2008128086A1 (en) * 2007-04-12 2008-10-23 Cv Therapeutics, Inc. Ranolazine for enhancing insulin secretion
KR20100038322A (ko) * 2007-05-31 2010-04-14 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료 방법
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
EP2515880B1 (en) * 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
EP2480234B1 (en) 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
EP2524688B1 (en) 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016144855A1 (en) * 2015-03-07 2016-09-15 Innophos, Inc. Leavening composition to replace aluminum based leavening acids
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110859843A (zh) * 2019-12-17 2020-03-06 卓和药业集团有限公司 一种治疗动脉硬化合并心绞痛的药物组合物及制备方法
CN111000818A (zh) * 2020-01-04 2020-04-14 东莞市东阳光仿制药研发有限公司 一种雷诺嗪组合物及其制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
CN118680891A (zh) * 2024-08-20 2024-09-24 湖州亚瑟制药有限公司 一种用于治疗心绞痛的制剂组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6242918A (ja) * 1985-08-20 1987-02-24 Kaken Pharmaceut Co Ltd 持続性製剤
IE69270B1 (en) * 1989-01-03 1996-08-21 Sterling Winthrop Inc Controlled-release low-dose aspirin
ATE142497T1 (de) * 1989-06-23 1996-09-15 Syntex Inc Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1505977B1 (en) * 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes

Also Published As

Publication number Publication date
RU2007125656A (ru) 2009-01-20
JP2008526879A (ja) 2008-07-24
BRPI0606403A2 (pt) 2009-06-23
US20060177502A1 (en) 2006-08-10
UA90875C2 (ru) 2010-06-10
ZA200705530B (en) 2008-10-29
CN101098682A (zh) 2008-01-02
RU2384332C2 (ru) 2010-03-20
MX2007008162A (es) 2007-07-24
KR20070093988A (ko) 2007-09-19
WO2006074398A3 (en) 2007-02-22
CA2593593A1 (en) 2006-07-13
AU2006203890A1 (en) 2006-07-13
GEP20094784B (en) 2009-09-25
WO2006074398A2 (en) 2006-07-13
IL184460A0 (en) 2007-10-31
EP1841411A2 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
NO20074037L (no) Farmasoytiske formuleringer med vedvarende frigivelse
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
CY1111729T1 (el) Υπογλωσσιο επικαλυμμενο δισκιο
ATE528989T1 (de) Kristalline feste rasagilin-base
NO20075628L (no) Farmasøytiske formuleringer
SE0301372D0 (sv) Novel compounds
NO20076347L (no) Nye regimer for orale monofasiske befruktningshindrene midler
EA200802008A1 (ru) Фармацевтические композиции
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
DK1879623T3 (da) Genterapi til rygmarvssygdomme
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
RU2398586C3 (ru) Фармацевтическая композиция
DK1910325T3 (da) Nye farmaceutisk forbindelser
ME01459B (me) Postupak za doziranje medikamenata
EA200801414A1 (ru) Кальцилитические соединения
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
DK1587478T3 (da) Farmaceutisk sammensætning
NO20063293L (no) Farmasoytiske forbindelser
NO20044448L (no) Nye forbindelser
UY30801A1 (es) Compuestos calciliticos
DE502005004020D1 (de) Membranspannfutter
ITMI20031619A1 (it) Amplificatore di rilevamento perfezionato.
NO20091386L (no) Fenyloksyanilinderivater
ATE438381T1 (de) Zolpidemtabletten
DK2081944T3 (da) Nye morfin-derivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application